Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shane Morgan

Physician Assistant, Medical Lincoln, RI Physician Assistant

NPI 1437142213 CMS profile 10983830

3 Wake Robin Rd Unit 5, Lincoln, RI 02865

Open in the dashboard

General payments

$24,182

1,279 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shane Morgan of Lincoln, RI is reported in the CMS Open Payments database as having received $24,182 across 1,279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,996 261
2024 General $5,732 286
2023 General $5,679 305
2022 General $4,348 245
2021 General $3,428 182

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shane Morgan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Shane Morgan were reported at $4,996. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Shane Morgan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,428 $156 $41–$563 $132
2022 $4,348 $185 $55–$649 $149
2023 $5,679 $199 $58–$717 $160
2024 $5,732 $206 $62–$740 $164
2025 $4,996 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,824 320 payments
  2. Janssen Biotech, Inc. $3,628 185 payments
  3. LEO Pharma Inc. $2,399 99 payments
  4. Genzyme Corporation $1,331 53 payments
  5. Pfizer Inc. $1,295 91 payments
  6. Incyte Corporation $1,287 56 payments
  7. Novartis Pharmaceuticals Corporation $1,243 62 payments
  8. Sun Pharmaceutical Industries Inc. $1,142 54 payments
  9. Lilly USA, LLC $1,101 50 payments
  10. UCB, Inc. $985 41 payments
  11. Other $4,948 268 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,331 1,265 payments
  2. Education $851 14 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $3,042 129 payments
  2. ADBRY $1,990 82 payments
  3. SKYRIZI $1,918 110 payments
  4. RINVOQ $1,765 141 payments
  5. DUPIXENT $1,642 63 payments
  6. OPZELURA $1,192 55 payments
  7. CIBINQO $993 70 payments
  8. SOTYKTU $955 61 payments
  9. TALTZ $912 42 payments
  10. EUCRISA $886 72 payments
  11. Other $13,018 783 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,249

Median for Physician Assistant: 241

Drug cost

$739,341

Median for Physician Assistant: $4,110

Branded share of claims

14.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Risankizumab-Rzaa Brand 12 $236,468
Humira(Cf) Pen Adalimumab Brand 13 $174,936
Otezla Apremilast Brand 22 $99,702
Dupixent Pen Dupilumab Brand 16 $82,957
Rinvoq Upadacitinib Brand 13 $80,964
Fluocinonide Generic 149 $8,997
Clobetasol Propionate Generic 118 $6,141
Ketoconazole Generic 337 $6,133
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 160 $4,508
Metronidazole Generic 67 $3,819

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$120,238

Medicare's payments for the services billed

Medicare patients

677

Average age 75

Services billed

3,976

293 women, 384 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 21%
Cancer 19%
Atrial fibrillation 18%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,143 — —
DUPIXENT
$625 16 —
ADBRY
$566 — —
SKYRIZI
$417 12 —
RINVOQ
$404 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

1,279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record